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Purpose: To compare the efficacy of intravitreal injection of bevacizumab alone or combined 
with intravitreal triamcinolone as the primary treatment for cases with diabetic macular edema 
(DME).
Methods: Ninety eyes were enrolled in one of the three study arms; where intravitreal 
  triamcinolone acetonide (IVT) was used in group I, IVT/intravitreal bevacizumab (IVT/IVB) 
in group II, and IVB in group III. The visual acuity (VA) and central macular thickness (CMT) 
were used as the outcome measures, where the results of each group were calculated and com-
pared with the results of the other.
Results: There was significant improvement in the VA in the three study groups at weeks 6 and 12; 
with regards to the intraocular pressure (IOP), there was significant difference at week 6 in the 
IVT and IVT/IVB groups, and at week 12 in IVT/IVB group, and nonsignificant difference at 
week 6 in the IVB group and at week 12 in IVT and IVB groups.
Conclusion: From this study, we conclude that IVB is an effective drug for treatment of DME, 
and has a long lasting effect when compared with IVT and when compared with combined 
IVT/IVB; adding IVT does not affect the outcome measures except for elevating the IOP in 
treated patients in the early post-injection period.
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Introduction
Diabetic macular edema (DME) is a leading cause of visual impairment in diabetic 
patients,1 and its prevalence has been reported to be 10%.2
The Early Treatment Diabetic Retinopathy Study showed that macular laser 
photocoagulation (MPC) is effective in reducing the risk of visual loss in eyes with 
clinically significant macular edema.3
However, the improvement in visual acuity occurs in only about 17% of treated 
eyes, and cases show three lines of improvement in visual acuity, and MPC results 
in laser scars that tend to increase with time, thus decreasing the likelihood of visual 
improvement,3 and laser treatment has limited results in eyes with diffuse DME.3,4
Intravitreal triamcinolone (IVT) shows to have a beneficial effect on DME,5,6 
with a probable mechanism of increase in tight junction proteins, which diminish 
vessel leakage by a local vasoconstrictive effect,7,8 and angiostatic properties through 
inhibition of vascular endothelial growth factor (VEGF),9 but the treatment success 
is limited by ocular complications.10–15
Recent research has revealed the role of VEGF in inducing vascular 
hyperpermeability.16–20Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Bevacizumab, a humanized full-length monoclonal 
antibody that inhibits all isoforms of VEGF, has been used 
for DME.21
In this randomized, three-arm clinical trial, we compared 
the efficacy of intravitreal injection of bevacizumab (IVB) 
alone or combined with IVT as the primary treatment of 
cases with DME.
Patients and methods
This prospective study included 90 eyes of 90 different 
patients with clinically significant macular edema based on 
the Early Treatment Diabetic Retinopathy Study definitions,1 
after being approved by the Ethics committee board of 
Minoufiya University. Patients were divided randomly into 
three study groups: group I (IVT), group II (IVT/IVB), and 
group III (IVB). Each group included 30 eyes, and all cases 
were followed up for 12 weeks.
Exclusion criteria were: previous laser treatment, pre-
vious intraocular injection, previous intraocular surgery, 
history of glaucoma or ocular hypertension, and significant 
media opacity.
Complete ocular examination in the form of measurement 
of the best corrected visual acuity, intraocular pressure (IOP), 
slit lamp biomicroscopy, funduscopy, and central macular 
thickness (CMT) measurement using optical coherence 
tomography (Stratus OCT, version 4.0.7, Carl Ziess Meditec 
Inc, Jena, Germany).
Intravitreal injections were performed under complete 
sterile conditions using bovidine iodine 10% for eyelid 
skin and 5% for ocular surface wash, then after complete 
  draping, surface anesthesia was applied and intravitreal injec-
tion was performed as follows: for group I (IVT), 0.1 mL 
(4 mg) triamcinolone (Kenacort-A, SmithKline Beecham, 
an affiliated company to GalaxoSmithKline, London, UK)   
was injected in the inferotemporal quadrant; for group II 
(IVT/IVB), 1.25 mg bevacizumab in 0.05 mL (Avastin; 
Gemetech Inc, San Fransisco, CA), which was previously 
prepared in 27-gauge sterilized needle, was injected in the 
superotemporal quadrant, and 2 mg triamcinolone 0.05 mL 
was injected in the inferotemporal quadrant using 27-gauge 
needle in the same sitting; for group III (IVB), 1.25 mg 
bevacizumab in 0.05 mL was injected in the inferotemporal 
quadrant; for complete masking, a needleless syringe was 
pressed against the globe at the superotemporal quadrant in 
groups I and III; and all injections were done once and not 
repeated in the follow-up period.
Examination of best corrected visual acuity, IOP, 
detection of anterior chamber reaction, lens opacity, and 
  funduscopy were performed at day 1, and weeks 1, 6, and 12 
after injection; and detection of macular thickness in 1 mm 
circle centered around the fovea was done at the week 6 and 
week 12 follow-up.
Topical mixed antibiotics and steroids (tobramycin 0.3% 
and dexamethazone 0.1%) were applied for 1 week, and 
topical β-blocker was used to control the IOP at or below 
22 mm Hg in the early post-injection period.
Change in the best corrected visual acuity and CMT were 
taken as the outcome measures, and complications from 
intravitreal injection were recorded.
Statistical analysis was performed using SPSS Statis-
tics version 10 (IBM Corporation, Somers, NY) software, 
where descriptive measures were used for the pre- and post-
injection data; paired t-test was used to detect the statistical 
difference between the pre- and the post-injection data; 
one-way ANOVA (analysis of variance) test was used to 
detect the statistical difference in the outcome measures at 
weeks 6 and 12; and the least significant difference post hoc 
test was used to detect the statistical difference between the 
results of each pair of the study groups at the week 6 and 
week 12 follow-up.
Results
For all the study patients, the mean age was 57.64 ± 7.23 
years, with a minimum of 43 and maximum of 76 years; 
males were 53 (58.89%), and females were 37 (41.11%); 
patients with proliferative diabetic retinopathy (PDR) 
were 46 (51.11%), and those with nonproliferative diabetic 
  retinopathy (NPDR) were 44 (48.89%).
For group I (IVT), the mean age was 57.67 ± 7.19 years, 
with a minimum of 43 and maximum of 76 years; males were 
18 (60%), and females were 12 (40%); patients with PDR were 
14 (46.67%), and those with NPDR were 16 (53.33%).
For group II (IVT/IVB), the mean age was 57 ± 7.44 years, 
with a minimum of 45 years and a maximum of 75 years; 
males were 19 (63.33%), and females were 11 (36.67%); 
patients with PDR were 18 (60%), and those with NPDR 
were 12 (40%).
For group III (IVT), the mean age was 57 ± 7.3 years 
with a minimum of 44 and a maximum of 73 years; males 
were 16 (53.33%), and females were 14 (46.67%); patients 
with PDR were 20 (66.67%), and those with NPDR were 
10 (33.33%), demographic and clinical features of the study 
groups are shown in Table 1.
The descriptive data of the pre-injection visual   acuity, IOP, 
and CMT results, and those at week 6 and 12   post-injection in 
the three study groups were recorded as shown in Table 2.Clinical Ophthalmology 2011:5
Table 1 Demographic and clinical features of the study groups
Group Number Age Gender Diabetic retinopathy
Mean ± SD Male Female PDR NPDR
group i 30 57.66 ± 7.19 18 12 14 16
group ii 30 57.66 ± 7.44 19 11 12 18
group iii 30 57.60 ± 7.30 16 14 20 10
Total 90 57.64 ± 7.23 53 37 46 44
Abbreviations: PDr, proliferative diabetic retinopathy; nPDr, nonproliferative diabetic retinopathy; sD, standard deviation.
Table 2 Descriptive statistics of pre- and post-injection data in 
the three study groups
Variable Group I Group II Group III
VA
Before 0.18 ± 0.12 0.19 ± 0.13 0.22 ± 0.12
6 weeks 0.21 ± 0.11 0.23 ± 0.13 0.25 ± 0.13
12 weeks 0.20 ± 0.10 0.33 ± 0.17 0.28 ± 0.13
IOP
Before 14.83 ± 2.34 15.67 ± 2.86 15.47 ± 2.93
6 weeks 16.97 ± 2.47 17.80 ± 2.48 15.63 ± 2.62
12 weeks 15.03 ± 2.09 15.07 ± 2.05 15.13 ± 2.21
CMT
Before 492.30 ± 145.91 477.70 ± 153.38 445.06 ± 123.87
6 weeks 463.20 ± 124.16 444.66 ± 131.94 410.70 ± 106.24
12 weeks 471.53 ± 148.44 348.80 ± 113.25 383.83 ± 115.42
Note: Values are mean ± standard deviation. 
Abbreviations: VA, visual acuity; iOP, intraocular pressure; CMT, central macular 
thickness.
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Comparing the pre-injection to the post-injection results 
at weeks 6 and 12 with regards to visual acuity, IOP, and CMT 
in the three study groups revealed the following.
•	 Group I (IVT). With regards to the visual acuity, there 
was high significant difference between the pre- and post-
injection results at week 6 (P = 0.001); however, this dif-
ference was only significant at week 12 (P = 0.015). With 
regards to the IOP, there was a high significant difference 
between the pre- and post-injection results at week 6 
(P = 0.001); however, the difference was not significant 
at week 12 (P = 0.227). With regards to the CMT, there 
was a high significant difference between the pre- and 
post-injection results at weeks 6 and 12 (P = 0.001, and 
P = 0.003, respectively).
•	 Group II (IVT/IVB). With regards to the visual acuity, 
there was a high significant difference between the pre- 
and post-injection results at weeks 6 and 12 (P = 0.001 for 
both). With regards to the IOP, there was a high significant 
difference between the pre- and post-injection results at 
week 6 (P = 0.001); however, the difference was only 
significant at week 12 (P = 0.019). With regards to the 
CMT, there was a high significant difference between 
the pre- and post-injection results at weeks 6 and 12 
(P = 0.001 for both).
•	 Group III (IVB). With regards to the visual acuity, there 
was a high significant difference between the pre- and 
post-injection results at week 6 and 12 (P = 0.001 for 
both). With regards to the IOP, there was no significant 
difference between the pre- and post-injection results at 
weeks 6 and 12 (P = 0.258 and P = 0.169, respectively). 
With regards to the CMT, there was a high significant 
difference between the pre- and the post-injection 
results at weeks 6 and 12 (P = 0.001 for both). See 
Table 3.
Two cases in group I and one case in group II had IOP 
greater than 22 mm Hg for which topical β-blockers were 
used for 2 weeks, minimal anterior chamber reaction was 
detected in one case in groups I and II that resolved within 
1 week without extra new medications, neither cataracts nor 
other complications were noted in the follow-up period in 
all the study groups.
Comparing the visual acuity results at week 6 between 
the three study groups, there was no significant difference 
(P = 0.151), and also between each pair of the three study 
groups; however, at week 12, there was high significant dif-
ference (P = 0.004), and between each pair, there was high 
significant difference between groups I and II (P = 0.001), 
significant difference between groups I and III (P = 0.039), 
and no significant difference between groups II and III 
(P = 0.201).
Comparing the CMT results at week 6 between the 
three study groups, there was no significant difference 
(P = 0.121), and between each pair of the three study 
groups, there was significant difference between groups 
II and III only (P = 0.04); however, at week 12, there was 
high significant difference (P = 0.001), and between each 
pair, there was high significant difference between groups 
I and II (P = 0.001), significant difference between groups 
I and III (P = 0.009), and no significant difference between 
groups II and III (P = 0.287). These results are shown in 
Tables 4 and 5.Clinical Ophthalmology 2011:5
Table 3 Paired sample test comparing pre- and post-injection data in the three study groups
Variable Significance (two-tailed)
Group I Group II Group III
VA pre- and post-injection at 6 weeks 0.001 0.001 0.000
VA pre- and post-injection at 12 weeks 0.015 0.000 0.000
iOP pre- and post-injection at 6 weeks 0.000 0.000 0.258
iOP pre- and post-injection at 12 weeks 0.227 0.019 0.169
CMT pre- and post-injection at 6 weeks 0.000 0.000 0.001
CMT pre- and post-injection at 12 weeks 0.003 0.000 0.000
Abbreviations: VA, visual acuity; iOP, intraocular pressure; CMT, central macular thickness.
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Table 4 AnOVA test for the post-injection data in the three study groups
Variable Sum of squares Mean square Significance
VA 6 weeks post-injection Between groups
Within groups
Total
8.745E-02
1.966
2.053
4.372E-02
2.260E-02
0.151
CMT 6 weeks post-injection Between groups
Within groups
Total
57474.200
1154499.400
1211973.600
28737.100
13270.108
0.121
VA 12 weeks post-injection Between groups
Within groups
Total
0.244
1.814
2.058
0.122
2.085E-02
0.004
CMT 12 weeks post-injection Between groups
Within groups
Total
239820.956
1397254.433
1637075.389
119910.478
16060.396
0.001
Abbreviations: AnOVA, analysis of variance; VA, visual acuity; CMT, central macular thickness.
Discussion
Intravitreal injections are commonly used for treatment of 
DME. In this study we evaluated the results of both drugs 
used in the study, alone or combined, and compared the 
results to reach the best intravitreal drug that can be used 
safely and has the longest duration of action.
At week 6, there was a high significant improvement in 
visual acuity with all the study groups, and at week 12, this 
high significant improvement was maintained in the IVB 
and IVT/IVB groups only; this is similar to the results of 
Soheilian et al22 in 2007; however, in the IVT group this 
high significant improvement was not maintained.
IVT alone had improved the visual acuity of the treated 
patients at week 6, but this level was not maintained at 
week 12, which gives IVB an upper hand over IVT for 
treatment of DME with regard to the longer duration of 
action.
With regards to the IOP, there was a high significant 
increase at week 6 in the IVT and IVT/IVB groups, and this 
increase was maintained in the IVT/IVB group but at a low 
level at week 12; however, in the IVB group, there was no 
significant increase in the IOP at weeks 6 and 12, which adds 
to the drawbacks of IVT alone or when combined with IVB, 
making IVB alone more safe. IOP elevation with IVT was 
also documented in other studies.10–15
The increase in the IOP in the IVT/IVB and IVT groups 
could be attributed in part to the relatively large volume of 
intravitreal injection (0.1 mL) compared with the 0.05 mL 
volume of injections in the IVB group.
With regards to the CMT, there was a high significant 
decrease in the CMT at weeks 6 and 12 in all the study 
groups. This is similar to the results of Soheilian et al22 
in 2007 (where they had a significant improvement of the 
CMT at week 6 in the IVB and the IVT/IVB groups) and 
to the results of Ahmadieh et al23 in 2008 (where they had 
significant improvement in the CMT at weeks 6 and 12 in 
the IVB and IVT/IVB groups). However, the mean CMT for 
the IVT group was more at week 12 (471.33 µm) compared 
with that at week 6 (463 µm), and for groups II and III the 
CMT was lower at week 12 than at week 6. This maintained 
decrease in the CMT at week 12 in groups II and III was 
attributed to bevacizumab; however, IVT alone showed a 
greater increase in CMT at week 12 than at week 6.
IVB has an upper hand in its maintained effect on visual 
acuity, and CMT improvement at week 12, a benefit that 
could not be achieved by IVT alone. Also, the hazard of Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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elevating the IOP, especially at week 6, adds to the draw-
backs of IVT in the treatment of DME.
Comparing the three study groups with regards to the 
two outcome measures, visual acuity and CMT, we found 
no difference at week 6; however, at week 12, there was high 
significant difference between the three study groups, which 
supports the idea of having a better intravitreal drug. This is 
against the results of Ahmadieh et al23 in 2008, who found no 
significant difference in the CMT and visual acuity between 
the IVB and the IVB/IVT groups.
On comparing the results of the outcome measures for 
each pair of drugs, we found that there was a significant dif-
ference in the maintained improvement in visual acuity and 
the decrease in the CMT at week 12 on using IVB alone or 
combined with IVT. While this significant difference was 
not observed with IVT alone, this confirms the better and 
maintained effect of IVB over IVT in the treatment of DME 
without additional benefit of combining IVT to IVB.
We conclude that IVB is an effective drug for treatment 
of DME and has a long-lasting effect compared with IVT and 
combined IVT/IVB. Adding IVT does not affect the outcome 
measures except for elevating the IOP in treated patients in the 
early post-injection period; however, the maintained effect of 
these intravitreal drugs needs long-term follow-up studies.
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